HPV vaccine shows promise in cutting cervical lesion risk for HIV-Positive women

NCT ID NCT03284866

Completed Disease control Sponsor: AIDS Malignancy Consortium Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether the HPV vaccine can help prevent high-grade cervical lesions (precancerous growths) in women living with HIV who were already being treated for HPV. About 536 women took part, receiving either the HPV vaccine or a placebo. The goal was to see if the vaccine could lower the chance of these lesions coming back or developing into cancer. Results suggest the vaccine may offer extra protection beyond standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AIDS-RELATED HUMAN PAPILLOMAVIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical squamous intraepithelial neoplasia HIV infectious disease human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

African Cancer Institute at Stellenbosch

Cape Town, South Africa
Moi University School of Medicine

Eldoret, Kenya
UNC Project Malawi

Lilongwe, Malawi
Uganda Cancer Institute

Kampala, Uganda
University of Zimbabwe

Harare, Zimbabwe
University of the Witwatersrand

Johannesburg, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.